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Background: The incidence of lung cancer (LC) is reported to be higher in patients with rheumatoid arthritis (RA).
The present study investigated whether or not RA altered the clinical manifestation of LC.
Methods: In this retrospective, cohort study, a total of 23 patients with both RA and LC (RA + LC group), and
6,570 patients with primary LC alone (LCA group), were identified from records at Taipei Veterans General Hospital
between 1993 and 2002. Data about clinical characteristics, smoking habit, tumor location, LC histology, staging,
and survival, were compared between the 2 groups.
Results: There was no significant difference in mean age at LC diagnosis between the RA + LC and LCA groups
(70.2 vs 67.6 years; p = 0.154). Adenocarcinoma was the major histologic type in both groups, especially among
women. There was no significant difference in histology, location, or staging of LC between the RA + LC and LCA
groups. In the RA + LC group, all patients had RA before LC was diagnosed; pulmonary fibrosis was noted in
3 patients, 1 of whom had secondary Sjogren’s syndrome. Median survival in the LCA group was not significantly
different from that in the RA + LC group (10 [95% confidence interval, CI, 9.6, 10.4] vs 11 [95% CI, 3.7, 18.3]
months; p = 0.69); the relative risk of LCA compared with RA + LC for survival was 0.938 (95% CI, 0.555, 1.585).
The incidence of LC in RA patients in our hospital was 1.32% (23 of 1,740 patients).
Conclusion: RA has no influence on LC stage and does not shorten the survival of LC patients. [J Chin Med Assoc
2005;68(5):216–220]
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Introduction
Rheumatoid arthritis (RA) is the most common
systemic autoimmune disorder, and is characterized
by chronic inflammation of the synovial membranes
of multiple joints and a varying degree of systemic
involvement; women are affected more often than
men, by a ratio of 2.4:1.1 Eighty percent of patients
with RA have high titers of rheumatoid factor (RF;
anti-IgG immunoglobulin), and about 15–30% have
elevated antinuclear antibodies (ANAs).2 The age-
matched mortality rate in RA patients is up to twice
that in the general population.1 It has been well
documented that RA increases the risk of malignancies,
especially hematopoietic, lung and prostate cancers,
but studies on whether RA has a direct, causative role
in such malignancies are still required.3–5 The aims
of the present study were to summarize the clinical
characteristics of lung cancer (LC) in patients with
RA, and to determine whether or not RA is a risk factor
or indicator of poor prognosis in LC.
Methods
Study population
Taipei Veterans General Hospital is a general teaching
hospital in Taiwan with more than 2,500 beds.
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A total of 6,593 patients with LC at this hospital
during the period 1993–2002 were identified from a
computerized, inpatient-chart record system. Patients
were classified into 2 groups: those with both RA and
LC (RA + LC group), and those with primary LC
alone (LCA group). The diagnosis of LC in each case
was confirmed by cytohistologic examination of
samples taken from the original tumor or metastases.
RA was diagnosed according to 1987 revised American
Rheumatism Association criteria for the classification
of RA. Detailed medical records for all patients
admitted during this period, and diagnosed with RA
and LC, were reviewed. Data were collected regarding
age, gender, smoking status, serum RF titer, ANA
titer, tumor location, histology, and staging, and
treatment and survival. Examinations for LC staging
included chest and upper abdominal computed
tomography (CT) scans, brain CT scans, and bone
scans. Chest radiograms and CT scans were reviewed
to illustrate the lung manifestations in patients with
RA and LC. Mortality in hospital inpatients and
outpatients was identified through the linkage of
medical records to the national register of deaths.
All eligible RA patients were treated with non-
steroidal anti-inflammatory drugs, with or without
disease-modifying antirheumatic drugs. LCs were
treated with surgery, chemotherapy, and/or
radiotherapy, depending on histologic type and
staging.
Statistical analysis
The Wilcoxon rank-sum test was adopted for
continuous variables, and the Chi-squared test or
Fisher’s exact test was adopted for category variables.
LC survival was measured from the date of LC diagnosis
to the date of death or last follow-up. Survival curves
were calculated with the Kaplan-Meier method. The
log-rank test was used for a survival comparison between
different groups of patients. A p value less than 0.05
was considered statistically significant. Statistical
calculations were performed using SPSS version 11.0
(SPSS Inc, Chicago, IL, USA).
Results
Demographic data
Among 6,593 subjects with primary pulmonary
carcinoma, a total of 23 cases of RA were identified
(0.35%). Other collagen-vascular diseases were also
identified, including Sjogren’s syndrome (n = 13),
polymyositis/dermatomyositis (6), systemic lupus
erythematosus (6), and progressive systemic sclerosis
(3). On the other hand, 23 of the 1,740 patients with
RA (1.32%) at our hospital had LC. Bronchiolar
carcinoma was not found in the RA + LC group, but
was found in 2.4% of patients in the LCA group.
The RA + LC group comprised 23 patients (12
males and 11 females) with a history of RA for 1–20
years before the diagnosis of LC was made. Mean age
at the time of LC diagnosis was 70.2 years (range, 38–
85 years), with males diagnosed at an older mean age
than females (72.8 [range, 38–85] vs 67.6 [48–84]
years; p = 0.431). Thirteen of the 23 patients (56.5%)
were current or previous smokers. Twenty patients
had undergone serum RF tests, and all except 1 had
serum RF titers > 40 IU/mL. Seventeen patients had
undergone a serum ANA examination, and 8 (47.1%)
had a value > 1:80.
Among the 6,570 patients in the LCA group,
5,161 were males of mean age 69.1 years, and 1,409
were females of mean age 62.2 years. Approximately
2-thirds of patients in the LCA group were smokers
(Table 1).
Table 1. Demographic data for patients with rheumatoid arthritis and lung cancer (RA + LC) and for patients with primary
lung cancer alone (LCA)
RA + LC (n = 23) LCA (n = 6,570) p
Male/female, n (%) 12/11 (52.2/47.8) 5,161/1,409 (78.6/21.4) 0.005†
Mean age, yr (range) 70.2 (38–85) 67.6 (19–100) 0.154‡
Male 72.8 (38–85) 69.1 (20–100) 0.031‡
Female 67.6 (48–84) 62.2 (19–94) 0.212‡
Smoking status, n (%)* 0.259§
Yes 13 (56.5) 3,118 (67.6)
No 10 (43.5) 1,496 (32.4)
*Including current or previous smokers; †Fisher’s exact test; ‡Wilcoxon rank-sum test; §Chi-squared test.
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Tumor histology, location and staging
The most common histologic type of LC found in RA
patients was adenocarcinoma (52.2%), especially in
women (8 of 11 female patients; 72.7%), followed by
squamous cell carcinoma (13.0%), and small cell LC
(13.0%); upper lobe involvement was more common
than lower lobe involvement, and the most common
tumor location was the left upper lobe (29.2%). Re-
garding cancer staging, 78.2% of RA + LC patients and
82.3% of LCA patients had locally advanced or
metastatic disease (Table 2). However, there were no
significant differences between the 2 groups regarding
tumor histology, location, and staging. The initial
metastatic sites in patients with RA + LC were bone
(n = 8), liver (6), lung (4), adrenal gland (2), skin (2),
and brain (1). Eight patients had pleural effusion,
but samples from only 5 patients yielded malignant
cells. One patient had recurrent adenocarcinoma or
secondary LC 4 years after the initial tumor resection,
and another patient had multiple primary cancers,
including cervical cancer and malignant lymphoma.
RA manifestations
Regarding the pulmonary manifestations of RA,
Caplan’s nodules were not found in any of the 23
patients. Three patients had chest CT findings of
pulmonary fibrosis, and 1 of these patients had
secondary Sjogren’s syndrome; however, none of the
RA patients had symptomatic pulmonary fibrosis be-
fore LC was diagnosed.
Survival
The median survival of patients with RA + LC was 11
months (95% confidence interval [CI], 3.7, 18.3),
whereas that of patients with LCA was 10 months
(95% CI, 9.6, 10.4) (p = 0.69; Figure 1).
Discussion
The incidence of LC in RA patients in our hospital was
1.32%, but was 0.03% in the general population in
Taiwan in 1999. The mean age of patients with RA +
LC was greater than that of patients with LCA (70.2
vs 67.6 years; p = 0.228; Table 1). LC was equally
distributed between the upper and middle-lower lobes
in RA + LC patients (Table 2). Smoking is one of the
major risk factors for LC, and is also assumed to be a
common risk factor for RA and LC.2 ANAs occurred
more than twice as frequently in RA + LC patients than
Table 2. Lung cancer (LC) characteristics in patients with rheumatoid arthritis and LC (RA + LC) and in patients with
primary lung cancer alone (LCA)
RA + LC (n = 23) LCA (n = 6,570) p*
Histology, n (%)
Adenocarcinoma 12 (52.2) 2,796 (42.5) 0.352†
Squamous cell carcinoma 3 (13) 1,791 (28.4) 0.126†
NSCLC, type not specified 3 (13) 749 (11.4) 0.741‡
SCLC 3 (13) 712 (10.8) 0.733‡
Adenosquamous carcinoma 2 (8.7) 57 (0.9) 0.018‡
Bronchiolar carcinoma 0 155 (2.4) 1.000‡
Carcinoma, cell type not specified 0 234 (3.6) 1.000‡
Location, n (%)
RUL 5 (20.8) 1,773 (31.5) 0.310†
RML 3 (12.5) 416 (7.4) 0.242‡
RLL 5 (20.8) 1,006 (17.9) 0.785‡
LUL 7 (29.2) 1,557 (28.0) 0.775†
LLL 4 (16.7) 858 (15.2) 0.771‡
Staging, n (%)
I 4 (17.4) 804 (14.6) 0.765‡
II 1 (4.3) 168 (3.1) 0.512‡
III 5 (21.7) 1,668 (30.4) 0.370†
IV 13 (56.5) 2,855 (51.9) 0.662†
*Through Bonferroni adjustments, the levels of significance are p < 0.007 for histology, p < 0.010 for location, and p < 0.013 for staging;
†Chi-squared test; ‡Fisher’s exact test. LLL = left lower lobe; LUL = left upper lobe; NSCLC = non-small cell lung cancer; RLL = right lower
lobe; RML = right middle lobe; RUL = right upper lobe; SCLC = small cell lung cancer.
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in the overall population of RA patients (66.7% vs 30%
of patients).2 This suggests that LC in RA has some
relationship with the autoimmune reaction.
The risk of LC is reported to increase 1.2- to 1.5-
fold in RA patients,3–5 and while the current study also
suggests that RA may have a causative role in LC,
further studies into the potential carcinogenic link
between RA and LC are needed. It is important to
differentiate the pleuropulmonary manifestations of
RA from thoracic malignancies. When pulmonary
nodules are noted in RA patients, it is recommended
that tissue samples are obtained for pathologic
proof. Indeed, in 1 of our patients, misdiagnosis of a
rheumatoid nodule led to a delay in diagnosing the
malignancy. Rheumatoid nodules are well circum-
scribed, and are found most commonly in subcutane-
ous tissue, but less often in viscera. The pathologic
features of rheumatoid nodules are the same, re-
gardless of their location in the body. Such nodules
are an uncommon manifestation of pleuropulmon-
ary rheumatoid disease (0.2% by chest X-ray and 4% by
chest CT scan).6,7 Rheumatoid nodules are usually
associated with advanced RA, and with multiple
subcutaneous nodules in the elbows or elsewhere.
Pulmonary rheumatoid nodules may be solitary or
multiple, and are usually located peripherally in relation
to the pleura or interlobular septa.
CT evidence of pulmonary fibrosis was noted in
only 3 of our patients, 1 of whom had secondary
Sjogren’s syndrome, and radiologically overt pulmon-
ary fibrosis was found by chest X-ray in only 1–5%
of RA patients in a large series in another report.8
Minor pulmonary fibrosis is common in RA, and a
report on open lung biopsies performed in volunteers
Figure 1. Kaplan-Meier estimates for the survival of patients with
rheumatoid arthritis and lung cancer (RA + LC) or primary lung
cancer alone (LCA).
with RA documented pulmonary fibrosis in 60% of
patients.9 Dawson et al10 reported high resolution CT
(HRCT) evidence of fibrosing alveolitis, most
frequently of a reticular pattern, in 19% of hospital
outpatients with RA. None of the previously suggested
risk factors for fibrosing alveolitis were confirmed.
When dyspnea and bilateral basal chest crackles are
present in an RA patient, even without restrictive
changes or chest radiographic abnormalities, prompt
investigation with chest HRCT is needed to detect
pulmonary fibrosis.
Pleuritis or pleural effusion is the most frequent
manifestation of rheumatoid disease in the thorax.8,9
For unknown reasons, pleural effusion together with
rheumatoid disease has a strong predisposition towards
men. In our RA + LC patients, 4 men and 4 women
presented with pleural effusion, and 5 of them had ma-
lignant cells in the pleural fluid. However, no patients
had the typical findings of rheumatoid pleurisy, such as
low glucose level, high RF titer in the pleural fluid, and
elongated, multinucleated macrophages, with necrotic
background material, on cytologic examination.
In this study, although there was no precise
comparison between RA disease activity before and
after chemotherapy or radiotherapy, we found that
most patients had less need of medical treatment for
RA during cancer therapy. This can be attributed to
the immunosuppressive effects of chemotherapy and
radiotherapy, which decrease autoimmune disease
activity.
In summary, there were no significant differences
in the clinical characteristics of LC, including staging,
histology, and anatomic location, between LC patients
with or without RA. The survival time of patients with
RA + LC was similar to that of patients with LCA.
Prospective studies are needed to confirm whether or
not RA has a negative influence on LC prognosis.
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